Showing results (51-60 of 87) with videos related to
Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 27, 2009
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102G K Philips, S Halabi, B L Sanford, et al.American Journal of Clinical Oncology|August 26, 1998
Undetectable serum prostate-specific antigen associated with metastatic prostate cancer: a case report and review of the literatureA A Safa, D M Reese, D M Carter, et al.Prostate Cancer and Prostatic Diseases|July 23, 2014
Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetateW Kim, J O Jones, M Diamond, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2001
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancerP W Kantoff, S Halabi, D A Farmer, et al.Urology|August 15, 2001
Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomyG D Grossfeld, E J Small, D P Lubeck, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survivalE J Small, A McMillan, M Meyer, et al.Blood|January 1, 1985
A monoclonal antibody that inhibits activation of human Hageman factor (factor XII)E J Small, J A Katzmann, R P Tracy, et al.Prostate Cancer and Prostatic Diseases|June 25, 2014
Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-TE J Small, C S Higano, P W Kantoff, et al.Cancer|February 19, 2000
A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181N A Dawson, M Conaway, S Halabi, et al.Cancer|June 1, 1994
A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinomaE J Small, J W Frye, M J Wilkinson, et al.Pageof 9